Inotek Report issue

For profit Phase 2 Phase 3
Founded: Lexington MA United States (1996)
Status: Acquired by Rocket Pharma Limited (2017)

Organization Overview

First Clinical Trial
2004
NCT00271765
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Inotek Pharmaceuticals Corp. | Inotek Pharmaceuticals Corporation

Active Ingredients

Drugs in Phase 3 Trials (2)

timolol (blocadren) (2 trials)

trabodenoson (5 trials)

Drugs in Phase 2 Trials (2)

ino-1001 (2 trials)

latanoprost (xalatan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Heart Diseases (Phase 2)

Hypertension (Phase 3)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Ocular Hypertension (Phase 3)

Postoperative Complications (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4